Home » Stocks » Castle Biosciences

Castle Biosciences, Inc. (CSTL)

Stock Price: $49.71 USD -0.26 (-0.52%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 978.40M
Revenue (ttm) 62.54M
Net Income (ttm) 7.10M
Shares Out 19.68M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $49.71
Previous Close $49.97
Change ($) -0.26
Change (%) -0.52%
Day's Open 50.10
Day's Range 49.44 - 50.37
Day's Volume 83,992
52-Week Range 15.26 - 55.31

More Stats

Market Cap 978.40M
Enterprise Value 823.38M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.68M
Float 13.76M
EPS (basic) 0.56
EPS (diluted) -0.21
FCF / Share 0.90
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.61%
Payout Ratio n/a
Shares Short 733,752
Short Ratio 3.29
Short % of Float 5.33%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 62.21
PS Ratio 15.64
PB Ratio 6.59
Revenue 62.54M
Operating Income 7.43M
Net Income 7.10M
Free Cash Flow 15.73M
Net Cash 155.02M
Net Cash / Share 7.88
Gross Margin 71.24%
Operating Margin 11.88%
Profit Margin 10.90%
FCF Margin 25.14%
ROA 2.95%
ROE 9.22%
ROIC 36.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(10.64% upside)
Current: $49.71
Target: 55.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth127.62%65.67%-
Gross Profit44.5617.498.83
Operating Income7.33-3.84-10.90
Net Income5.28-6.37-12.37
Shares Outstanding8.581.911.90
Earnings Per Share-0.21-5.33-8.08
Operating Cash Flow7.02-12.30-12.23
Capital Expenditures-0.94-0.28-0.49
Free Cash Flow6.08-12.57-12.73
Cash & Equivalents98.854.481.21
Total Debt25.1224.5018.60
Net Cash / Debt73.72-20.02-17.39
Book Value85.11-56.57-50.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Castle Biosciences, Inc.
Country United States
Employees 133
CEO Derek J. Maetzold

Stock Information

Ticker Symbol CSTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: CSTL
IPO Date July 25, 2019


Castle Biosciences, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.